Cyclooxygenase (COX)-1 or -2 and specific prostaglandin (PG) synthases catalyze the formation of various PGs. We investigated the expression and activity of COX-1 and -2 during granulocyte-oriented maturation induced by all-trans-retinoic acid (ATRA) of NB4 cells, originated from a human acute promyelocytic leukemia (APL), and in blasts from APL patients. The expression of COX isoenzymes or prostaglandin synthases was also investigated in circulating granulocytes and human bone marrow. COX-1 was expressed and enzymatically active in NB4 cells and primary blasts. COX-1 mRNA and protein were induced by ATRA. COX-1 protein increased approximately 2-3.5-fold by culture day 3 in NB4 cells and primary blasts, while basal COX-2 expression was very low and unaffected by ATRA. COX-1-dependent PGE 2 biosynthesis increased during differentiation approx. 5-fold. Indomethacin and the selective COX-1 inhibitor SC-560, but not selective COX-2 inhibition, impaired NB4 differentiation, reducing NADPH-oxidase activity, CD11b and CD11c expression. The immunohistochemistry of granulocytes and myeloid precursors in the bone marrow showed a large prevalence of COX-1 as compared to COX-2. In conclusion, COX-1 is induced during ATRA-dependent maturation and appears to contribute to myeloid differentiation both in vitro and ex vivo, and COX-1 activity may potentiate the differentiation of human APL.
Introduction
Prostanoids are biologically active metabolites of arachidonic acid (AA), formed through the sequential action of phospholipases, cyclooxygenase (COX)-1 or -2, and terminal prostaglandin (PG) synthases, which generate PGE 2 , PGF 2a , PGD 2 , PGI 2 or thromboxane (TX)A 2 , known as prostanoids. 1 In spite of structural and functional homologies, COX-1 and -2 are encoded by different genes and subserve distinct functions: COX-1 is the constitutive isoform, 1 while COX-2 is largely inducible. 1 However, this paradigm has many exceptions: COX-1 can be regulated during lymphoid maturation, 2, 3 while COX-2 is stably expressed in the brain, reproductive tissues, kidney and thymus. 1 Circulating leukocytes diversely express COX isoforms: activated granulocytes and monocytes upregulate COX-2, releasing PGE 2 and TXA 2 . 3 Increasing evidence suggests a role for COX and prostanoids in hematopoiesis: CD34 þ stem cells express COX-1 and synthesize PGE 2 . 4 Prostaglandins participate to the intrathymic development of mouse and possibly human T cells. 2, 3 Metabolically active COX-1 and -2 are expressed during human megakaryopoiesis. 4 PGE 2 enhances hemoglobinization of erythroid cells. 5 Human monoblastic cell lines differentiated in vitro toward monocytes enhance mainly TXA 2 biosynthesis, [6] [7] [8] [9] [10] [11] [12] [13] although the COX isoform involved is presently unknown.
A vitamin A derivative, all-trans-retinoic acid (ATRA) and its receptor, the retinoic acid receptor (RAR) a, play an important role during the granulocytic differentiation.
14 This role is also highlighted by the capacity of ATRA to fully differentiate promyelocytic cell lines and primary blasts from acute promyelocytic leukemia (APL) both in vitro and in vivo. 15 Therefore, ATRA has been a major advance in the combined treatment of human APL. Among the different human APLderived cell lines, NB4 cells are maturation-inducible by ATRA and bear the diagnostic chromosomal translocation t (15;17) , observed in approx. 95% of human APL. 16 The t(15;17) translocation disrupts RARa gene, generating a RARa fusion protein, implicated in hampering the expression of genes involved in granulocytopoiesis.
14 Therefore, NB4 cells are highly representative of the human APL pathophysiology. 16 Furthermore, NB4 cells are different from other leukemic lines such as the myeloblastic HL-60, which lacks the t(15;17) and modulates different genes than NB4 when induced to differentiate by ATRA. 17 Few and sometimes conflicting data on prostanoids and COX isoforms are available with respect to ATRA-induced granulocytic differentiation. The U937 or J744.1 monocytoid cell lines showed prostanoid induction only when ATRA was combined with other agents, 10, 18, 19 while a recent report showed upregulation of COX-1 upon ATRA stimulation in U937. 20 ATRA alone increased PGE 2 synthesis from HL-60 cells, 21 although the COX isoform involved has not been characterized. COX genes were not listed among the ones modulated by ATRA in NB4 using microarray analysis. 17 Heterogeneity in the phenotype of cell lines (monoblastic, myeloblastic, promyelocytic) or in the differentiating stimuli may account for such inconsistencies. To explore the possible involvement of COX and prostanoids along granulocytic differentiation, we studied maturation of NB4 cells in the presence of ATRA, as a model closely reflecting the human APL. In parallel, we studied primary APL blasts from patients differentiated in vitro, circulating granulocytes and normal human bone marrow samples. A new role for COX-1 in granulocytic myelopoiesis is suggested by this study, that could impact on the therapeutic strategies of human APL.
Materials and methods

NB4 cell cultures
The NB4 cell line (see Supplementary material) (kindly provided by Dr M Lanotte, through the courtesy of Dr Koeffler, CedarsSinai Medical Center, Los Angeles, CA, USA), carrying the t (15, 17) 16 was cultured in suspension with RPMI medium/10% FCS and differentiated with ATRA (Sigma Chemicals, St Louis, MA, USA), in serum-free conditions using Opti-MEM supplementation (GIBCO, Invitrogen Corporation), as previously described. 22 For inhibitor studies, cultures were set up in the presence of vehicle, indomethacin, SC-560, NS-398 or PGE 2 (all from Cayman Chemical, Ann Arbor, MI, USA), as detailed. Inhibitors and PGE 2 were reconstituted in ethanol as 1000 Â stocks and freshly added to cultures every 48 h. Controls contained the same amounts of ethanol, without significant effects on the proliferation or differentiation. For AA loading experiments, washed cells were incubated with HBSS/0.1% BSA/10 mM AA (Cayman Chemical), and supernatants were collected. 2, 4 For dose/response experiments with inhibitors, cells were preincubated with HBSS/BSA containing various concentrations of drugs and then 10 mM AA were added. PGE 2 and TXB 2 were measured in cell supernatants using previously validated RIA.
2,4
Patients, primary APL blast purification and granulocyte isolation After informed consent according to the INSERM Institutional Review Board, primary APL cells were obtained from bone marrow aspirates of five APL patients presenting 480% of blasts at diagnosis, and differentiated with 100 nM ATRA, as previously described. 23 The t(15;17) translocation was confirmed by RT-PCR amplification of the PML-RARa transcript. 23 Granulocytes were isolated from peripheral blood of four healthy subjects upon informed consent, by density-gradient centrifugation, as previously described. 22 Purity was determined by morphology (497% granulocytes).
mRNA and protein studies
Total RNA was extracted with TRIzol reagent (Gibco BRL, Life Technologies) and single-stranded cDNAs were obtained using Moloney murine leukemia virus reverse transcriptase (Pharmacia Biotech, Uppsala, Sweden) and random hexamers. PCR reactions were performed by standard procedures with primers for COX-1 or -2, and human b-actin, using previously described conditions. 2, 4 The expected DNA fragments were: 320 bp for COX-2, 290 bp for COX-1, 200 bp for b-actin. PCR products were identified by agarose gel electrophoresis and Southern blotting with specific oligonucleotides and high stringency conditions, as previously detailed. 2, 4 For immunoblots, washed cells were lysed in ice-cold buffer, as already detailed.
2,4 A measure of 20-50 mg of protein per sample were electrophoresed in 10% SDS-polyacrylamide gels, blotted onto nitrocellulose filters (Hybond, Amersham), incubated with monoclonal Abs anti-COX-1 or anti-COX-2, with peroxidase-conjugated anti-mouse IgG (Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA) and then revealed with ECL reagent (Amersham Corp., Arlington Heights, IL, USA), as detailed previously. 2, 4 Blots treated with anti-COX-2 Ab were revealed with the high sensitivity system Supersignal WestPico substrate (Pierce Biotechnology, Rockford, IL, USA). Densitometric analysis was performed using SigmaGel (SPSS, Chicago, IL, USA).
Immunohistochemistry and scanning electron microscopy
Immunohistochemistry was performed on cytocentrifuged cells by standard techniques, as previously detailed. 2, 4 Briefly, slides were fixed in ice-cold 70% methanol/30% acetone, treated with methanol/0.3% H 2 O 2 to block endogenous peroxidase and incubated with one of the following primary Abs: COX-1 polyclonal Ab, COX-2 polyclonal Ab, mPGES polyclonal Ab, cPGES polyclonal Ab and TXS polyclonal Ab, EP2 and EP4 (all from Cayman Chemical), or CD11c monoclonal Ab (Pantec, Torino, Italy). Indirect immunoperoxidase was performed using the ABC-peroxidase technique (Vector Laboratories, Burlingame, CA, USA). Immunofluorescence was detected with FITCgoat anti-mouse or anti-rabbit Abs (Dako, Milano, Italy). CD11b labeling only, was performed on viable cells in suspension. After incubation with fluorescent secondary antibodies, a drop of viable cell suspension was placed on a slide and observed on the microscope. Images were digitalized by a fluorescence Zeiss Axioskop microscope (Zeiss, Jena, Germany) equipped with an intensified CCD camera system (Photometrics, Tucson, AZ, USA). For scanning electron microscopy (s.e.m.) analysis, cells were treated as previously described, 24 observed and micrographed by a Philips XL30 scanning electron microscope.
Nitroblue tetrazolium assay NADPH-oxidase activity was studied with the nitroblue tetrazolium (NBT) assay, according to previously described technique. 23 Briefly, cells were pelleted, resuspended in complete medium containing 0.2% (w/v) NBT/10 À7 M PMA (both from Sigma), incubated at 371C for 30 min, spun down, the cell pellet dissolved 1 ml DMSO and ODs at 540 nm were measured. Sample values were expressed as fold increase, by dividing OD values of treated cells by OD values of vehicle-treated samples. Alternatively, NBT positivity was assessed by light microscopy after May-Grü mwald counterstain and expressed as % of NBTpositive cells.
Results
Cyclooxygenase expression and activity during NB4 cell differentiation
Untreated NB4 cells expressed COX-1 and COX-2 protein and mRNAs (Figures 1a,b and 2b-e), although COX-1 signal was more pronounced, synthesized prostanoids spontaneously and were able to utilize exogenous AA, raising prostanoid concentrations of approx. 10-folds. PGE 2 was the main product (180750 pg/10 6 cells, with AA loading) as compared to TXA 2 (110730 pg/10 6 cells). The nonselective COX-1/COX-2 inhibitor indomethacin (10 mM) inhibited by 495% basal prostanoid production. Due to the presence of COX-1 and COX-2 in NB4 cells, the selective COX-1 inhibitor SC-560 25 or the selective COX-2 inhibitor NS-398 26 were used to assess the relative contribution of each isoform to total PGE 2 synthesis. As shown by dose-response curves (Figure 2a) , COX-1 largely accounted for PGE 2 synthesis, while the contribution of COX-2 was o20%. The prevalence of COX-1 activity is consistent with the higher signal observed for COX-1 protein. Immunocytochemistry for prostanoid synthases showed a strong signal for the cytosolic PGE 2 synthase (cPGES) and, to a lesser extent, for the TXA 2 synthase (TXS), while the microsomal PGES-1 (mPGES) gave a weak positivity (Figure 1c-e) . Data on synthases are in agreement with the enzymatic activity of COX-1. In fact, cPGES and/or TXS are known to couple preferentially to COX-1 expression and activity. 4, 27 COX isoenzymes were then studied in NB4 cells differentiated by 100 nM ATRA for 5-7 days. ATRA switched NB4 morphology to a mature phenotype exhibiting smaller size, condensation and lobulation of the nuclei, high CD11b or CD11c expression and NBT-reduction activity (Figures 3-5) . mRNA for COX-1 was upregulated, peaking at day 2, when its expression was enhanced by approx. 3.5-fold compared to basal (Figure 2b ), while COX-2 mRNA signal, which was weak in untreated NB4 cells, was unaffected by ATRA (Figure 2c) . Consistently, COX-1 protein was maximally induced by day 3 of approx. 4-fold increase (Figure 2d ). Of note, human COX-1 migrated in immunoblots as a doublet, as already reported using the same Abs on different human cells. 28 COX-2 protein, barely detectable in untreated NB4, was unaffected by ATRA (Figure 2e) . In parallel to COX-1 protein induction, PGE 2 synthesis showed a major increase and peaked by day 3 of approx. 5-fold, while TXB 2 synthesis raised to a significantly lesser extent (Figure 2f ). Indomethacin (10 mM) blunted prosta- noid increases by 495%, SC-560 (10 mM) lowered the PGE 2 synthesis to the levels of untreated cells, while NS-398 (10 mM) did not affect prostanoid synthesis, indicating that COX-1 accounted for PGE 2 increase. The degree of the raise in prostanoid biosynthesis was directly dose-dependent on ATRA concentrations (Figure 2g ). Due to the prevalent increment of PGE 2 , the expression of PGE 2 receptor (EP) isoforms was investigated, showing the presence of EP2 and EP4 receptor subtype on NB4 cells (Figure 1f, g ).
Effect of COX-1 inhibition on ATRA-dependent NB4 maturation
To investigate whether the upregulation of COX-1 activity influenced NB4 maturation, the nonselective inhibitor indomethacin, the selective COX-1 inhibitor SC-560 or the selective COX-2 inhibitor NS-398, were added with 100 nM ATRA to cell cultures. Experiments were also performed using PGE 2 either alone, with 100 nM ATRA or with ATRA plus 10 mM SC-560. Cell morphology, CD11b or CD11c expression and NADPH-oxidase activity were studied as differentiation indexes. SC-560, NS-398 or indomethacin alone, for up to 5 days, did not cause apoptosis or increased cell cytotoxicity compared to controls. The combination ATRA/indomethacin or SC-560 comparably delayed maturation. Both 10 mM SC-560 (Figure 3a-c) and 10 mM indomethacin (data not shown) significantly increased the immature cells (20715 vs 62710% in ATRA and ATRA/SC-560 cultures, respectively, at day 5), reducing polynuclear cells (3777 vs 1078% of total cells in ATRA and ATRA/SC-560 cultures, respectively, at day 5). Inhibitor-treated cells were dysplastic, bearing an immature, large basophilic cytoplasm and a more mature, condensed nucleus (Figure 3b,c) . SC-560 with ATRA reduced the expression of CD11b and CD11c, affected the shape and surface morphology of NB4 cells and significantly lowered NBT-reduction capacity as compared to ATRA cultures (Figures 3d-j and 4a-d) . The effect of SC-560 was largely rescued by exogenous PGE 2 (100 nM and 1 mM) (Figures 3j and  4d) . PGE 2 alone, at the same concentrations, did not affect maturation (Figure 3j and data not shown) . Alternatively, NS-398 did not affect ATRA-induced maturation (Figure 3j and data not shown). Finally, 1 mM PGE 2 potentiated ATRA effect both functionally (Figure 3j ) and morphologically (polynuclear cells: 1873% in ATRA-treated cultures and 3074% in ATRA/PGE 2 , at day 4).
COX expression in primary APL blasts, peripheral granulocytes and bone marrow
To assess whether COX-1 upregulation of NB4 cells was strictly cell-line dependent or rather a mechanism occurring in vivo, primary blasts from APL patients were treated with 100 nM ATRA and studied for COX expression. Differentiation was confirmed by the NBT test (NBT-positive cells: 56720% at day 3 and 81711% at day 6). Consistent with NB4 data, COX-1 protein doubled by day 3 (270.7-fold increase vs untreated) and by day 6 COX-1 levels were 2.671.1-fold higher than controls (Figure 4e ). The percentage of NBT-positive cells was directly related to the intensity of the densitometric bands for COX-1 normalized for b-actin (r ¼ 0.76, n ¼ 8, Po0.05). Very low levels of COX-2 protein were detected on untreated blasts, and COX-2 expression was unaffected by ATRA (Figure 4e ). In peripheral granulocytes, which are the end-products of physiologic granulocytopoiesis, COX-1 and COX-2 mRNAs were detectable (Figure 5a ), although COX-1 protein was predominant both in immunoblots (data not shown) and immunohistochemistry (Figure 5b,c) . Detectable levels of COX-2 mRNA but not protein are consistent with previous observations in granulocytes. 29, 30 The cPGES isoform and TXS showed a strong positivity in granulocytes (Figure 5e,f) , which may be consistent with data showing a preferential coupling between COX-1 and TXS or cPGES. 4, 29 Finally, morphologically recognizable myeloid precursors in normal bone marrow, that is, band cells and metamyelocytes, stained intensively for COX-1 (Figure 5g,h) , indirectly confirming the large prevalence of COX-1 along the myeloid lineage.
Discussion
This is the first description of the upregulation of COX-1 protein and enzymatic activity in NB4 cells during granulocytic maturation and, more importantly, it has been shown that COX-1 is also induced in primary blasts from APL patients. COX-1 upregulation during granulocytic maturation was quite unexpected. COX-1 is largely considered constitutively expressed and ATRA has been reported to induce COX-2 in neuroblastoma or fibroblastic cell lines. 31 However, in agreement with our observations, COX-1 upregulation has been reported on different neuroblastoma cells. 32 By analyzing the COX-1 promoter, 33 we could not find any canonical RAR responsive element (RARE). Nevertheless, the COX-1 promoter contains two Sp1-binding sequences, necessary for COX-1 activity. 33 Interestingly, Sp1 is highly expressed during myeloid differentiation 34 and has been reported to mediate ATRA responsiveness of several genes devoid of RARE motifs, by interacting with RARs. [34] [35] [36] A similar mechanism may regulate COX-1 transcription upon ATRA-RAR interaction. Alternatively, other ATRA-responsive gene(s) may mediate COX-1 induction.
Our data show that PGE 2 is the main product of COX-1 activity during differentiation. PGE 2 injection to rats causes neutrophilia, 37 PGE 2 analogs increase survival of irradiated mice [37] [38] [39] and PGE 2 restores normal phenotype of granulocytemacrophage colony-forming cells (CFU-GM) in culture, from patients with chronic myeloid leukemia. 40 Altogether these data support a prodifferentiating role of PGE 2 in myelopoiesis. The antiproliferative effect of PGE 2 on CFU-GM 41 might be also consistent with a differentiating role that restricts proliferative potential. Agents that increase intracellular cAMP, including 25 mM PGE 2 , can differentiate ATRA-resistant NB4 sublines, 42, 43 and potentiate ATRA response of normal NB4 cells. 42 Consistently, we observed that as low as 1 mM PGE 2 potentiated the ATRA effect. It is therefore conceivable that PGE 2 may exert its differentiating action through cAMP, as already reported for Blymphocytes. 3 cAMP potentiates maturation, 44 or differentiates 45, 46 NB4 or HL-60 cells. Furthermore, the EP2 receptor potentiates ATRA-dependent differentiation of HL-60 cells. 47 Consistently, we found that NB4 cells expressed the EP2 and EP4 receptors, which signal through cAMP. 47 ATRA-induced, COX-1-dependent synthesis of PGE 2 from APL cells may be relevant for APL treatment, because PGE 2 has prodifferentiating activity when associated with ATRA, 48 ( Figure 5 ), and because, as shown in this work, COX-1 is upregulated in primary APL blasts. COX-1 activity and consequent enhancement of differentiation may thus represent a novel autocrine route and pharmaceutical target contributing to ATRA efficacy in APL. The EP agonist misoprostol is currently used in obstetric practice and gastric ulcers. Such agonist might be considered as possible differentiation-potentiating agent for a combined APL therapy. This might lower the dosage of ATRA, impact the incidence and severity of retinoic acid syndrome, and reduce the development of ATRA resistance. On the basis of our data, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) as analgesics/ antipyretics in ATRA-treated APL patients should be reconsidered, for NSAIDs inhibit COX-1 activity and therefore may lower ATRA efficacy. Therefore, selective COX-2 inhibitors might be a more appropriate choice in this context. In parallel with PGE 2 , we observed a minor increment of TXA 2 release from maturing NB4 blasts. TXA 2 is a potent prothrombotic agent. 49 It will be important to assess whether increased TXA 2 biosynthesis accompanies ATRA treatment in patients. Interestingly, thromboses can be associated with ATRA therapy, 50, 51 and the pathogenesis remains obscure. TXA 2 may contribute to these complications, and TXA 2 receptor antagonists 49 may represent a potential antithrombotic therapy/prophylaxis in APL. Aside from data on primary blasts, COX-1 prevalence in the myeloid lineage is indirectly supported by data on bone marrow and granulocytes. Selective COX-1 induction in murine bone marrow cells differentiated with GM-CSF has been reported. 16 In addition, indomethacin induces hyperplasia of immature hematopoietic cells in mice, which might be compatible with a maturation block in the differentiated compartment. 52 Granulocytosis has also been reported in COX-2-null mice. 53 It has been repeatedly shown that COX-2-null mice upregulate COX-1 in different organs, exaggerating COX-1-related, rather than COX-2-deficient phenotype, 54, 55 and therefore granulocytosis of COX-2-null mice might originate from compensatory COX-1 overexpression in the bone marrow.
In summary, we have shown that COX-1, but not COX-2, is the 'inducible' isoform during granulocytic differentiation of both NB4 cells and primary human APL blasts. A role for PGE 2 and TXA 2 as agents either promoting differentiation or contributing to ATRA-related thrombotic complications, respectively, might be hypothesized and should be further explored in APL patients to improve the risk/benefit profile of APL combination therapy.
